NEW YORK (GenomeWeb News) – Compugen will collaborate with Merck to develop a peptide that, based on recent in vitro and in vivo studies, potentially could be used in the treatment of inflammatory diseases and other indications.
The agreement covers additional research that Compugen will conduct on the CGEN-855 peptide, and gives Merck Serono an option to license it exclusively for worldwide development and commercialization.